Dr. Reddy's
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1984-01-01
- Employees
- -
- Market Cap
- $13.8B
- Website
- http://www.drreddys.com/
Coya Therapeutics Advances Treg Exosome Platform for Neurodegenerative Disease Treatment
Coya Therapeutics is advancing its regulatory T cell-derived exosome (Treg exosome) platform with plans to initiate GMP manufacturing of clinical batches by Q4 2025, positioning it for first-in-human trials.
Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost
Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility.
Dr. Reddy's Launches Toripalimab in India for Nasopharyngeal Carcinoma Treatment
Dr. Reddy's Laboratories has launched Toripalimab in India, an immuno-oncology drug approved for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
Dr. Reddy's and Hetero Partner with Gilead to Produce Generic HIV Drug Lenacapavir
Dr. Reddy's and Hetero have signed non-exclusive licensing agreements with Gilead to manufacture and market generic lenacapavir in 120 countries.
Dr. Reddy's Rituximab Biosimilar Receives Positive CHMP Opinion for EU Launch
Dr. Reddy's Laboratories has received a positive opinion from the EMA's CHMP for its proposed rituximab biosimilar, DRL_RI (ITUXREDI), paving the way for its launch in European markets.